Business
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and
About this update from Cabaletta Bio, Inc.
[{"type":"text","content":"PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that data from its two lead programs, DSG3-CAART and MuSK-CAART, will be presented at multiple upcoming scientific meetings in May 2022. The DSG3-CAART presentations will include Phase 1 clinical data from the ongoing DesCAARTes™ trial. The MuSK-CAART presentations will contain preclinical safety and activity studies to support potential clinical development of precision engineered T-cell therapy for MuSK-associated myasthenia gravis. Desmoglein 3 chimeric autoantibody receptor T (DSG3-CAART) cells are currently being evaluated in the Phase 1 DesCAARTes™ trial as a potential treatment for patients with mucosal pemphigus vulgaris (mPV). Details of the presentations are as follows: American Society of Gene & Cell Therapy 25th Annual Meeting at Walter E. Washington Convention Center in Washington, D.C. from May 16-19, 2022 Title: A Phase 1 Trial of Targeted DSG3-CAART Cell Therapy in Mucosal-Dominant Pemphigus Vulgaris (mPV) Patients: Early Cohort Data Abstract Number: 793Poster Number: Tu-298Date and Time: Tuesday, May 17, 2022, 5:30 p.m. – 6:30 p.m. ETPresenter: David J. Chang, M.D., Chief Medical Officer at Cabaletta Bio Title: Characterization of DSG3-CAART Cells Prior to & Following Adoptive Transfer in Mucosal Pemphigus VulgarisAbstract Number: 698Poster Number: Tu-203Date and Time: Tuesday, May 17, 2022, 5:30 p.m. – 6:30 p.m. ETPresenter: Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio In addition to these poster presentations, Aimee Payne, M.D., Ph.D., a Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, co-chair of the Cabaletta Bio Scientific Advisory Board and co-founder at Cabaletta Bio, will deliver a presentation titled “Genetically Engineered CAAR T Cell Therapies for B cell-mediated Autoimmune Diseases” on Wednesday, May 18, 2022, at 9:12 a.m. ET. Society For Investigative Dermatology 2022 Annual Meeting at Oregon Convention Center in Portland, OR from May 18-21, 2022 Title: A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris (mPV) patients: Preliminary dataAbstract Number: LB952 Date and Time: Fri...